With 20.10% CAGR, Global Gene Therapy Market Size to Surpass USD 7247.58 million by 2028 - Comprehensive Research Report by Facts & Factors

Facts and Factors estimate that the global gene therapy market will increase from its expected value of USD 2,415.10 million in 2021 to USD 7247.58 million in 2028, at a compound yearly growth rate (CAGR) of nearly 20.10% during the forecast period. The study examines the market's drivers, restraints, and challenges as well as the impact each has on demand over the forecasted period. The paper also looks at new potential in the market for gene therapy.

A gene is a fundamental component of the genetic code that carries a set of instructions for carrying out a specific function in living things. Gene therapy treats blood disorders, chronic illnesses, infectious infections, and cancer. Gene therapy includes replacing unhealthy genes with faulty ones within the patient's body to treat or halt the progression of a disease. The rise in chronic diseases, such as cancer, rare illnesses, genetic disorders, and others, is one of the major drivers of the gene therapy market's expansion. The need for cell and gene therapy has grown as a result of a sharp rise in the incidence of rare diseases worldwide. The global market for gene therapy is anticipated to expand at a CAGR of 20.10% during the forecast period due to the increase in demand for it.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚𝐧 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 @https://www.fnfresearch.com/sample/gene-therapy-market

The demand for novel treatments has expanded along with the prevalence of rare diseases, which has fueled the growth of the gene therapy sector. Ex-vivo gene therapy is becoming more popular for neurological treatments, which will accelerate the expansion of the gene therapy market. The gene therapy industry is also anticipated to be influenced in the coming years by the rising use of genome engineering in a number of treatments as well as the expanding use of gene modification in biotechnology applications. The global gene therapy market is expected to be hindered by high gene therapy costs and a lack of standardization.

𝐃𝐢𝐯𝐢𝐬𝐢𝐨𝐧𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

Based on the type of vector, therapy, gene, application, and geography, the global gene therapy market is segmented. The market is split into viral vectors and non-viral vectors based on the type of vector used. Viral vectors will be the market leader among these in 2021. The market is split into In Vivo Therapy and Ex Vivo Therapy according to the type of therapy. In vivo therapy is anticipated to grow at the quickest rate throughout the projected period in 2021.

The market is segmented into Antigen, Cytokine, Tumour Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others based on the kind of gene. In 2021, the antigen sector will rule this market. The market is segmented into Oncological Disorders, Rare Diseases, Neurological Disorders, and Other Diseases based on application. In 2021, the oncological illness category will rule out this
market.

𝐑𝐞𝐚𝐝 𝐛𝐮𝐲𝐧𝐨𝐰 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧@https://www.fnfresearch.com/buynow/su/gene-therapy-market

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬

Key players functioning in the global Gene Therapy market include Novartis AG, Gilead Sciences., Shanghai Sunway Biotech Co. Ltd., Adaptimmune Therapeutics plc., Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Adverum Biotechnologies Inc., Jazz Pharmaceuticals, Shenzhen SiBiono Genentech, Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Intellia Therapeutics, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Astellas Therapeutics Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, Unique N. V., Voyager Therapeutics, Inc., Merck and Co Inc., and Dendron Corporation.

𝐑𝐞𝐜𝐞𝐧𝐭 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬:

In October 2021, the National Institutes of Health, the Food and Drug Administration, ten pharmaceutical companies, and five non-profit groups launched a collaboration to speed up the discovery of gene therapy for the 30 million Americans who suffer from a rare disease. Such activities are anticipated to increase the demand for gene therapy.
In February 2021, BioMarin Pharmaceutical Inc. provided an update on its investigational gene therapy programs that are currently in clinical development. The Food and Drug Administration (FDA) submitted additional requests to the Company for information needed to remedy the clinical hold issued in September 2021 for the PHEARLESS Phase 1/2 trial of BMN 307.

𝐍𝐞𝐞𝐝 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧? 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐞𝐝 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭@https://www.fnfresearch.com/customization/gene-therapy-market

𝐆𝐥𝐨𝐛𝐚𝐥 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐚𝐬 𝐟𝐨𝐥𝐥𝐨𝐰𝐬:

𝐁𝐲 𝐕𝐞𝐜𝐭𝐨𝐫 𝐓𝐲𝐩𝐞

Viral Vector
Non-Viral Vector

𝐁𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐲

In Vivo Therapy
Ex Vivo Therapy

𝐁𝐲 𝐆𝐞𝐧𝐞 𝐓𝐲𝐩𝐞

Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth factors
Receptors
Others

𝐁𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧

Oncological Disorders
Rare Diseases
Neurological Disorders
Other Diseases

𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧

North America
The U.S.
Canada
Mexico
Europe
France
The UK
Spain
Germany
Italy
Nordic Countries
Denmark
Sweden
Norway
Benelux Union
Belgium
The Netherlands
Luxembourg
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Southeast Asia
Indonesia
Thailand
Malaysia
Singapore
Rest of Southeast Asia
Rest of Asia Pacific
The Middle East & Africa
Saudi Arabia
UAE
Egypt
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America

Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: sales@fnfresearch.com
Web: https://www.fnfresearch.com

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client's/customer's conviction in our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

This release was published on openPR.